AngioDynamics Q1 FY27 sales rise 6.9% to $80.9M; adjusted loss narrows to $0.04, FY27 guidance reiterated

ANGIODYNAMICS INC

2027-Q1 EPS reported -$0.17 revenue$80,915,000

Net sales $80.9M, up 6.9% YoY; Med Tech $39.9M (+13.2%) and Med Device $41.0M (+1.4%); GAAP loss per share $0.17 vs $0.26 a year ago.
Adjusted loss per share $0.04 vs $0.10; adjusted EBITDA $5.0M vs $2.2M; gross margin 59.4% (+410 bps), or 57.8% excluding tariff refunds; $34.0M cash, debt-free.
Auryon sales $18.9M (+14.7%), NanoKnife $8.3M (+29.0%), AlphaVac +37.4%, AngioVac -5.9%; Mechanical Thrombectomy $12.0M (+6.7%).
FY27 guidance reiterated: net sales $336-341M, Med Tech growth 12-15%, Med Device flat, gross margin 54-55%, adjusted EBITDA $13-16M, adjusted EPS -$0.29 to -$0.24.
Eric Honroth named President and CEO effective Nov 2, 2026, succeeding retiring Jim Clemmer; FDA IDE approved for RELIEF, a 40-patient NanoKnife IRE study in BPH.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.